Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy
European Journal of Haematology · 2024-01 · 112 (1) · 111-121
DOI: 10.1111/ejh.14068 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Haematology, 2023-08. Verfasst von Cecilia C S Yeung und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Cytopenia. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Background
Bone marrow (BM) assessment after CAR‐T cell immunotherapy infusion is not routinely performed to monitor adverse events such as cytopenias, hemophagocytic lymphohistiocytosis, or infections. Our institution has performed BM biopsies as part of CAR‐T cell treatment protocols, encompassing pre‐ and post‐treatment time points and during long‐term follow‐up.
Methods
We conducted a systematic retrospective review of BM abnormalities observed in samples from 259 patients following CAR‐T cell immunotherapy. We correlated BM pathology findings with mortality, relapse/residual disease, and laboratory values.
Results
At a median of 35.5 days post‐CAR‐T infusion, 25.5% showed severe marrow hypocellularity, and 6.2% showed serous atrophy, and peripheral blood cytopenias corroborated these observations. Marrow features associated with reduced disease burden post‐CAR‐T infusion include increased lymphocytes seen in 16 patients and an increase of macrophages or granulomatous response seen in 25 patients. However, a 100‐day landmark analysis also showed increased marrow histiocytes were associated with lower survival (median OS 6.0 vs. 21.4 months, p = .026), as was grade 2–3 marrow reticulin (18 patients) (median OS 12.5 vs. 24.2 months, p = .034).
Conclusions
These data represent the first systematic observations of BM changes in patients receiving CAR‐T cell immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
- Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
- Department of Medicine, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Cecilia C S Yeung, David W Woolston, Vicky Wu, Jenna M Voutsinas, Ryan Basom, Chris Davis, Alexandre V Hirayama, Kikkeri N Naresh
Zitieren
APA
Yeung, C. C. S., Woolston, D. W., Wu, V., Voutsinas, J. M., Basom, R., Davis, C., Hirayama, A. V., & Naresh, K. N. (2024). Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy. European Journal of Haematology, 112(1), 111-121. https://doi.org/10.1111/ejh.14068
Vancouver
Yeung CCS, Woolston DW, Wu V, Voutsinas JM, Basom R, Davis C, et al. Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy. European Journal of Haematology. 2024;112(1):111-121. doi:10.1111/ejh.14068
BibTeX
@article{Yeung2024,
author = {Yeung, Cecilia C S and Woolston, David W and Wu, Vicky and Voutsinas, Jenna M and Basom, Ryan and Davis, Chris and Hirayama, Alexandre V and Naresh, Kikkeri N},
title = {Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor‐T cell therapy},
journal = {European Journal of Haematology},
year = {2024},
volume = {112},
number = {1},
pages = {111--121},
doi = {10.1111/ejh.14068}
}
EUVIMED